Cystic fibrosis (CF), transmitted by a single autosomal recessive gene, affects 1 in 2500 of the population. A biochemical abnormality affects the quality of mucus, and results in pancreatic duct obstruction, and progressive lung damage as a result of respiratory infection. Thirty years ago it is probable that almost all affected babies died of pneumonia in the first two years of life. Over the past generation the prognosis has improved substantially for children fortunate enough to be diagnosed early, and some of these are now reaching adult life with relatively little lung damage. There is, however, still substantial illness and mortality in childhood, and much of this could be avoided by earlier diagnosis. The lungs are structurally normal at birth, but have a built-in tendency to progressive lung damage; by the time respiratory problems lead to a diagnosis irreversible lung damage may have been done.
About one case a day is born in the United Kingdom, the average paediatrician sees about one new case a year, and the average family doctor will have one new case in his practice in his working life.
The natural history of CF suggests the desirability of making a diagnosis before it becomes clinically obvious. The requirements of a screening programme are that it should be harmless, reliable, accurate, cheap, and acceptable to the very large number of unaffected people who will be subjected to it. None of the existing methods of diagnosis satisfy the last two criteria. The most widely used diagnostic test is the measurement of sodium or chloride content of sweat, the flow of which has been stimulated by pilocarpine iontophoresis. Other exocrine glands are, however, similarly affected, and Johnston (1956) reported Received May 12, 1969. that in CF the sodium content of parotid saliva was high.
The parotid salivary gland secretes continuously in the absence of specific stimulation, and its orifice is easily accessible. A micro-dual sodium sensitive electrode which could be used in the mouth was developed, and we proceeded to measure the saliva sodium concentration in a series of normals, heterozygous unaffected genetic carriers (i.e. parents), and cases of CF. The technique was described in detail by Saggers et al. (1967) . Results indicated that consistent and reliable measurements could be made, and that there was a clear distinction between the sodium levels in normals and heterozygotes on the one hand, and cases of CF on the other.
Measurements were next made on a series of 50 babies in the first week of life, but these showed a very wide scatter of readings at high levels in the normal, presumably due to immaturity of control mechanisms. The same 50 babies tested at 6 weeks showed a reduced but still substantial scatter, and a lower mean, but still well above the levels found in normal people in later life (Lawson, Saggers, and Chapman, 1967) . A third series of 50 babies was then tested in the clinics of the London Borough of Sutton at the age of 3-4 months, and it was found that by this age unstimulated parotid salivary sodium levels had reached maturity.
There was now a sufficient basis for a pilot trial of the technique, not only to confirm the findings on a larger scale, but to study the administrative problems of running such a programme. Screening was therefore offered to all 3-4-month-old babies in the London Borough of Sutton from February 1, 1968 1, , to January 30, 1969 Fig. 3 that the peak incidence of values is between 2 and 8 mEq/l., and that 9500 of values were below 10 mEq/l.
There is not, however, a sharp cut off at 15, and we propose in future to retest at a level of 13 mEq/l. which will give a retest rate of just over 5%. Fig. 4 shows the parotid sodium levels found in 56 patients with CF (outside this series) who had been reliably diagnosed by other means. It will be seen that in 12 tested in the fourth month of life there were no readings below 17 mEq/l.; and that in 44 children over this age there were 3 readings between 12 and 15 mEq/l. The ages of these 3 children were 4, 10, and 18 years.
The results of this pilot trial suggest that it would be well worth while running a large trial covering an area with 10,000 births per annum, when it could be expected that 4 cases would be diagnosed per annum. Such a trial is planned in this area.
There is no point in making an early diagnosis unless early action follows; and any such screening programme should be organically linked with a CF unit in the hospital service where any diagnostic problems which arise can be immediately sorted out, and where in the cases diagnosed a fully prophylactic programme can be started at once, including physiotherapy and respiratory tuition, pancreatin replacement therapy and dietary guidance, and prophylactic antistaphylococcal therapy. 
